
Daniel S. Chen MD PhD
Melanoma
Founder and CEO, Synthetic Design Lab, Inc Founder, Engenuity Life Sciences
Join to View Full Profile
Synthetic Design LabBurlingame, CA 94010
Dr. Chen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Cancer Immunotherapy, PD-L1, PD-1, Immunology, Drug Development, Biomarkers, Angiogenesis, Molecular Diagnostics, Biochips, Virology, Targeted Therapy, Melanoma Oncology
Specialties: Drug Development, Molecular Diagnostics, Translational Research
Medical Oncologist and Cancer Immunologist.
Education & Training
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2000 - 2003
- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1998 - 2000
- Keck School of Medicine of the University of Southern CaliforniaClass of 1998
- Massachusetts Institute of TechnologyBS, Biology, 1986 - 1990
Certifications & Licensure
- CA State Medical License 1999 - 2024
Awards, Honors, & Recognition
- https://www.pinterest.com/dschen5/dsc/
Clinical Trials
- Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer Start of enrollment: 2016 Mar 01
- Atezolizumab and Bevacizumab in Treating Patients with Rare Solid Tumors Start of enrollment: 2017 Mar 03
- A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma Start of enrollment: 2019 Sep 30
- Join now to see all
Publications & Presentations
PubMed
- Immunity as biophysics at the surface of a T cell.Daniel S Chen
Immunity. 2024-02-13 - 252 citationsThe cancer-immunity cycle: Indication, genotype, and immunotype.Ira Mellman, Daniel S Chen, Thomas Powles, Shannon J Turley
Immunity. 2023-10-10 - 10 citationsMaximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC).Michael B Atkins, Hamzah Abu-Sbeih, Paolo A Ascierto, Michael R Bishop, Daniel S Chen
Journal for Immunotherapy of Cancer. 2022-09-01
Journal Articles
- Differential Regulation of PD-L1 Expression by Immune and Tumor Cells in NSCLC and the Response to Treatment with Atezolizumab (Anti–PD-L1)Alan Sandler, David S Shames, Hartmut Koeppen, Jamie Chaft, Scott N Gettinger, Alexander Spira, Daniel S Chen, Naiyer A Rizvi, David R Spigel, Proceedings of the National Academy of Sciences
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialFehrenbacher, L, Spira, A, Ballinger, M, Kowanetz, M, Vansteenkiste, J, Mazieres, J, Park, K, Smith, D, Artal-Cortes, A, Lewanski, C, Braiteh, F, Waterkamp, D, He, P, ..., Lancet, 1/1/2016
Press Mentions
- Too Many Trials, Not Enough PatientsNovember 18th, 2019
- Drug Giant Tries New Tactic to Fight CancerMay 27th, 2019
- A Cure for Cancer: How to Kill a KillerNovember 4th, 2018
- Join now to see all
Committees
- Co-Organizer, SITC Immuno Engineering Initiative 2022 - Present
- co-organizer, SITC Deep Dive Series 2020 - Present
- Board of Directors, SITC (Society of Immunotherapy for Cancer) 2018 - 2022
- Co-Chair, CRI Cancer Immunotherapy Consortium 2016 - 2020
- Committee Chair, Society for Immunotherapy of Cancer 2012 - 2018
Professional Memberships
- Member
- Member
- Member
Other Languages
- Chinese (Mandarin)
Industry Relationships
- Founder, Bionic Cell Medicines2022 - Present
- Founder and CEO, Synthetic Design Lab2022 - Present
- Founder, Engenuity Life Sciences2022 - Present
- Chief Medical Officer, IGM Biosciences2018 - Present
- Vice President, Global Head for Cancer Immunotherapy, Genentech/Roche2006 - 2018
External Links
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: